LIXT insider transaction filings
LIXTE BIOTECHNOLOGY HOLDINGS, INC. — 27 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-02. Screen LIXT transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-02 | 4 | Stazzone Peter — Chief Financial Officer | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2026-07-02 | 4 | Sawyer Jason David — Director | Grant/award (A): 40,000 @ $0 | EDGAR |
| 2026-07-02 | 4 | Pursglove Geordan Garrett — CEO and Chairman of the Board, Director | Grant/award (A): 350,000 @ $0 | EDGAR |
| 2026-07-02 | 4 | Primus Guy Warren — Director | Grant/award (A): 15,000 @ $0 | EDGAR |
| 2026-07-02 | 4 | Holloway Michael Andrew — Director | Grant/award (A): 15,000 @ $0 | EDGAR |
| 2026-07-02 | 4 | Felix Lourdes — Director | Grant/award (A): 30,000 @ $0 | EDGAR |
| 2026-06-01 | 4 | Porter Stuart D — Director | Grant/award (A): 25,000 @ $0 | EDGAR |
| 2026-04-17 | 4 | Stazzone Peter — Chief Financial Officer | Grant/award (A): 50,000 · Disposition to issuer (D): 50,000 (derivative) | EDGAR |
| 2026-04-17 | 4 | Sawyer Jason David — Director | Grant/award (A): 25,000 · Disposition to issuer (D): 25,000 (derivative) | EDGAR |
| 2026-04-17 | 4 | Pursglove Geordan Garrett — CEO and Chairman of the Board, Director | Grant/award (A): 350,000 · Disposition to issuer (D): 350,000 (derivative) | EDGAR |
| 2026-04-17 | 4 | Primus Guy Warren — Director | Grant/award (A): 25,000 · Disposition to issuer (D): 25,000 (derivative) | EDGAR |
| 2026-04-17 | 4 | Holloway Michael Andrew — Director | Grant/award (A): 25,000 · Disposition to issuer (D): 25,000 (derivative) | EDGAR |
| 2026-04-17 | 4 | Felix Lourdes — Director | Grant/award (A): 25,000 · Disposition to issuer (D): 25,000 (derivative) | EDGAR |
| 2025-12-29 | 4 | Primus Guy Warren — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Felix Lourdes — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-09-04 | 4 | Stazzone Peter — Chief Financial Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-08-18 | 4 | Sawyer Jason David — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-08-18 | 4 | Holloway Michael Andrew — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-07-09 | 4 | Pursglove Geordan Garrett — CEO and Chairman of the Board, Director | Grant/award (A): 350,000 (derivative) @ $0 | EDGAR |
| 2025-07-09 | 4 | Yen Yun — Director | Grant/award (A): 10,000 (derivative) @ $0 · Grant/award (A): 11,632 (derivative) @ $0 | EDGAR |
| 2025-07-08 | 4 | Forman Stephen J. — Director | Grant/award (A): 10,000 (derivative) @ $0 · Grant/award (A): 7,754 (derivative) @ $0 | EDGAR |
| 2025-07-08 | 4 | Bernards Rene — Director | Grant/award (A): 10,000 (derivative) @ $0 · Grant/award (A): 10,662 (derivative) @ $0 | EDGAR |
| 2025-07-08 | 4 | Brown Regina — Director | Grant/award (A): 10,000 (derivative) @ $0 · Grant/award (A): 12,600 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | Yen Yun — Director | Grant/award (A): 8,777 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | Bernards Rene — Director | Grant/award (A): 8,045 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | Forman Stephen J. — Director | Grant/award (A): 5,851 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | Brown Regina — Director | Grant/award (A): 9,508 (derivative) @ $0 | EDGAR |
Recent 8-K events — LIXTE BIOTECHNOLOGY HOLDINGS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-07-31 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-10 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.02 — Unregistered Sales of Equity Securities 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-01 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-20 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=LIXT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →